Detection of recurrent phosphaturic mesenchymal tumors by using Ga-68 DOTATATE PET/CT

Year 2024, Volume: 10 Issue: 1 - January 2024, 144 - 148, 04.01.2024

Wardah Ashfaq Iqra Iftıkhar Mariam Fayyaz Mahnam Khızer Saira Fatıma Muhammad Numaır Younis

https://doi.org/10.18621/eurj.1273409

Abstract

Phosphaturic mesenchymal tumor is a rare clinical condition and often causes osteomalacia due to tumor. Its diagnosis is often significantly delayed due to its rare occurrence in addition to the generalized and vague symptoms of their presentation. A 19-year-old female with a history of left facial nerve palsy, generalized weakness and hoarseness of voice revealed a dense mass in her brain. In this case, we reported successful application of a Ga-68 labeled DOTATATE PET/CT scan to identify the primary site and distant metastases of phosphaturic mesenchymal tumors and show the diagnostic value of Ga-68 labeled DOTATATE PET/CT imaging for the rare tumors.

Keywords

Phosphaturic mesenchymal tumor, Ga-68 labeled DOTATATE PET/CT scan, osteomalacia

References

• 1. Ghorbani-Aghbolaghi A, Darrow MA, Wang T. Phosphaturic mesenchymal tumor (PMT): exceptionally rare disease, yet crucial not to miss. Autops Case Rep. 2017;7(3):32-37. doi: 10.4322/acr.2017.031.
• 2. Brandi ML, Clunie GPR, Houillier P, et al. Challenges in the management of tumor-induced osteomalacia (TIO). Bone. 2021;152:116064. doi: 10.1016/j.bone.2021.116064.
• 3. Lee DY, Lee SH, Kim BJ, et al. Usefulness of 68Ga-DOTATOC PET/CT to localize the culprit tumor inducing osteomalacia. Sci Rep. 2021;11(1):1819. doi: 10.1038/s41598-021-81491-2.
• 4. Moreno Romero M, Pérez Muñoz I, González Lizán F, Gallego Rivera JI, Valdivielso Cañas L. The phosphaturic mesenchymal tumor as a cause of oncogenic osteomalacia. Three cases and review of the literature. Rev Esp Cir Ortop Traumatol (Engl Ed). 2021:S1888-4415(21)00050-3. doi: 10.1016/j.recot.2020.12.004.
• 5. Qiu S, Cao LL, Qiu Y, et al . Malignant phosphaturic mesenchymal tumor with pulmonary metastasis: a case report. Medicine (Baltimore). 2017;96(17):e6750. doi: 10.1097/MD.0000000000006750.
• 6. Oyama N, Kojima-Ishii K, Toda N, et al. Malignant transformation of phosphaturic mesenchymal tumor: a case report and literature review. Clin Pediatr Endocrinol. 2020;29(2):69-75. doi: 10.1297/cpe.29.69.
• 7. El-Maouche D, Sadowski SM, Papadakis GZ, et al. 68Ga-DOTATATE for tumor localization in tumor-induced osteomalacia. J Clin Endocrinol Metab. 2016;101(10):3575-3581. doi: 10.1210/jc.2016-2052.
• 8. Fallahi B, Manafi-Farid R, Eftekhari M, et al. Diagnostic efficiency of 68Ga-DOTATATE PET/CT as compared to 99mTc-Octreotide SPECT/CT and conventional morphologic modalities in euroendocrine tumors. Asia Ocean J Nucl Med Biol. 2019;7(2):129-140. doi: 10.22038/AOJNMB.2019.39392.1263.
• 9. Chatterjee D, Bardia A, Pal R, Saikia UN, Bhadada SK, Radotra BD. Clinical, morphological and immunohistochemical analysis of 13 cases of phosphaturic mesenchymal tumor - A holistic diagnostic approach. Ann Diagn Pathol. 2021;54:151783. doi: 10.1016/j.anndiagpath.2021.151783.
• 10. Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30. doi: 10.1097/00000478-200401000-00001.
• 11. Pelo S, Gasparini G, Garagiola U, et al. Phosphaturic mesenchymal tumor, an unusual localization in head and neck. J Surg Case Rep. 2018;2018(5):rjy091. doi: 10.1093/jscr/rjy091.
• 12. Richardson AL, Richardson OK. Phosphaturic mesenchymal tumor: case report. Radiol Case Rep. 2019;14(12):1518-1524. doi: 10.1016/j.radcr.2019.09.027.